Evidence map›Paper›PMID 8780385›Full record

ArticleThe American journal of pathology1996

Scatter factor binds to thrombospondin and other extracellular matrix components.

K Lamszus, A Joseph, L Jin, Y Yao, S Chowdhury, A Fuchs, P J Polverini, I D Goldberg, E M Rosen

Abstract read
In one paragraph

Article in The American journal of pathology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.Proceedings of the National Academy of Sciences of the United States of America · 2003
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

K LamszusDepartment of Radiation Oncology, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA.
A Joseph
L Jin
Y Yao
S Chowdhury
A Fuchs
P J Polverini
I D Goldberg
E M Rosen
Long Island Jewish Medical Center · US

Funding

SCATTER FACTOR AND AIDS-RELATED KAPOSIS SARCOMAR01CA064416 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI POLVERINI, PETER · 1994 to 1998
–
REGULATION OF SCATTER FACTOR EXPRESSION IN BREAST CANCERR01CA064869 · NCI · LONG ISLAND JEWISH MEDICAL CENTER · PI ROSEN, ELIOT M · 1994 to 1997
–
NCI NIH HHS CA-64416NCI NIH HHS CA-64869
6 · The paper itself

Abstract

Scatter factor (SF) is an angiogenic growth factor that stimulates motility and invasion of carcinoma cells. SF is present in the extracellular matrix (ECM) of breast cancers, where it might act to promote tumor cell invasion and angiogenesis. To investigate how SF is incorporated into the ECM, we studied the binding of SF to various ECM components using a solid-phase binding assay based on the SF enzyme-linked immunosorbent assay. We found that SF binds to a variety of ECM molecules, with different binding capacities. The highest SF binding capacities were observed for thrombospondin-1 (TSP-1), fibronectin (Fn), and heparan sulfate proteoglycan, although SF did not bind to albumin. Mature two-chain SF and precursor single-chain SF bound approximately equally well to TSP-1 and Fn. Moreover, two SF alpha-chain peptides (NK1 and NK2) both bound to TSP-1 and Fn, suggesting that the whole SF molecule is not required for binding. Based on binding competition assays, TSP-1 exhibited higher affinity for SF than did nine other ECM molecules, including Fn and heparan sulfate proteoglycan. Although heparin in solution potently inhibited the binding of SF to TSP-1-coated surfaces, even very high concentrations of heparin could not elute SF already bound to TSP-1. SF binding was modulated by binding interactions among ECM molecules (TSP-1-Fn, TSP-1-collagen I, and Fn-collagen I), suggesting that the matrix capacity to bind SF depends upon its exact composition. SF bound in a dose-dependent fashion to ECMs secreted by three human breast carcinoma cell lines. Binding of SF to matrices from all three cell lines was significantly inhibited by preincubation of the matrices with antibodies against TSP-1, whereas antibodies against several other ECM components were less effective or ineffective in inhibiting SF binding. In addition, TSP-1 markedly inhibited chemotaxis of microvascular endothelial cells toward SF and SF-induced angiogenesis in the rat cornea neovascularization assay. Our findings suggest that 1) SF interacts with a variety of ECM components, 2) high affinity SF-TSP-1 interactions may mediate the binding of SF to the breast cancer matrix, and 3) the SF-TSP-1 interaction may contribute to modulation of angiogenesis. Possible implications of these findings for tumor angiogenesis are discussed.

Indexed as

AnimalsBinding, CompetitiveBreast NeoplasmsCell Adhesion MoleculesChemotaxisDose-Response Relationship, DrugExtracellular MatrixFemaleHeparinHepatocyte Growth FactorHumansMembrane GlycoproteinsNeovascularization, PhysiologicRatsStructure-Activity RelationshipThrombospondinsCell Adhesion MoleculesHeparinHepatocyte Growth FactorMembrane GlycoproteinsThrombospondins

Identifiers

PMID8780385
PMCPMC1865139
OpenAlexW163717267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.